Skip to main content

AI news

Tempus expands BMS oncology data and AI research agreement

Tempus says Bristol Myers Squibb signed a multi-year agreement to license de-identified oncology data through 2031 and use its Lens AI research platform. The announcement describes research access and hoped-for drug-discovery benefits; it does not report a new approved therapy or measured clinical improvement.

Tempus AI

BMS oncology data agreement

Business & Adoption

Published (date only)

Updated

1 source

Primary source · Tempus AI · October 23, 2026

Opens Tempus AI in a new tab. Read it there before you rely on the summary above.

Read the original

Free, email only

Unlock the full brief free.

  • What to check before you trust this story, written down
  • Each verified source, with why it matters and who published it
  • A note whenever a source has been withdrawn
  • Thirty days of stories to browse, not seven
Continue with Google and subscribeContinue with Apple and subscribe

Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.

This is not an account: there is no password, and the unlock is a cookie in this browser. You also join Work Worth Doing, Demetri Panici's newsletter, every week: what I built and what changed in AI. We'll email you a link to confirm, and you can unsubscribe in one click. The same signup unlocks every free tool on the site. How your email is handled.

Already subscribed? Enter the same email to unlock this browser. You won't be signed up twice.